BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Idera Pharmaceuticals, Inc. 

167 Sidney Street

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-679-5500 Fax: 617-679-5592


SEARCH JOBS

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances.

For more information, visit www.iderapharma.com.

 Key Statistics


Email: info@iderapharma.com
Ownership: Public

Web Site: Idera Pharmaceuticals, Inc.
Employees:
Symbol: IDRA
 









 Company News
Idera Pharmaceuticals, Inc. (IDRA) Presents Preclinical Data at American Association for Cancer Research Showing IMO-8400 Inhibits Tumor Growth And Survival Signaling In B-Cell Lymphoma Cells With Oncogenic MYD88 L265P Mutation 4/8/2014 7:25:35 AM    More...
Idera Pharmaceuticals, Inc. (IDRA)'s IMO-8400 Safe, Well Tolerated In Phase 2 Skin Disease Study 3/28/2014 6:40:21 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) Announces Expansion Of Pipeline Into Two Orphan Autoimmune Diseases 3/13/2014 8:03:10 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) Reports Fourth Quarter And Year End 2013 Financial Results And Provides Corporate Update 3/13/2014 6:54:22 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) Announces Appointment Of Julian Baker And Dr. Kelvin Neu To Its Board Of Directors 3/12/2014 7:30:58 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) To Host Conference Call And Webcast To Report Fourth Quarter And Full Year 2013 Financial Results On Thursday, March 13, 2014 3/6/2014 7:29:51 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) To Present At The Cowen and Company 34th Annual Health Care Conference 2/26/2014 7:38:47 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) To Present At The 2014 RBC Capital Markets’ Global Healthcare Conference 2/19/2014 6:56:11 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) Announces Closing Of Public Offering Of Common Stock And Pre-Funded Warrants 2/11/2014 8:45:57 AM    More...
Idera Pharmaceuticals, Inc. (IDRA) To Present At 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/6/2014 7:13:00 AM    More...
12345678910...

//-->